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Abstract 
The purpose of this study was to determine if health care providers in the primary 
care setting were identifying individuals with increased risks for Alzheimer’s disease and 
if the utilization of genetic screening related to the disease was being offered to those 
individuals.  Extensive research into the genetic etiology of Alzheimer's disease has 
proven that some genetic factors are causative and increase a person's risk of developing 
the disease.  The need for further comprehensive assessments for those with increased 
risk of developing Alzheimer’s disease, such as genetic testing, is imperative in 
identifying the disease-causing gene mutations associated with the disease.  These risk 
factors include increased age, family history, diabetes, hypertension, obesity, smoking, 
depression, cognitive inactivity, physical inactivity, low education, and specific genetic 
markers (APOE-e4).  Focusing efforts in the primary care setting on identifying patients 
who are at increased risk of developing the disease prior to the clinical onset allows for 
the utilization of genetic screening.  Identifying cognitively healthy individuals ages 50-
75, who are at increased risk of developing Alzheimer's disease-related to their age or 
genetic variations in genes, will aid providers with diagnosis and clarification of risk for  
those individuals and their families.  The current study addressed these issues with an 






longevity, enhancing the quality of life, and reducing health care cost. 
Research was conducted to determine if genetic screening was being utilized in 
the primary care setting for individuals who are at increased risk for developing 
Alzheimer's disease.  This was done by utilization of a quantitative survey.  Strict caution 
was taken once approval was granted by the Institutional Review Board at Mississippi 
University for Women, this was  to ensure participant privacy and anonymity as data was  
collected. The researchers provided questions in the form of a survey utilizing 
SurveyMonkey, Inc. which included demographic data, the determination of provider 
assessments, the evidence of genetic screening being offered, the cognitive assessments 
used, the reason genetic screening is not utilized, and the follow-up care provided for 
those who choose genetic screening. The study had 20 respondents in this sample, which 
was also considered a limitation in the research.   Based on this sample of respondents 
and upon completion of the data, the study determined that genetic testing was not being 
utilized by primary care providers in the state of Mississippi for individuals with 
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The purpose of this study was to determine if health care providers in the primary 
care setting were identifying individuals with increased risks for the disease, and to 
determine if the utilization of genetic screening related to Alzheimer's disease was being 
offered to those individuals.  Extensive research into the genetic etiology of Alzheimer's 
disease has proven that some genetic factors are causative and increase a person's risk of 
developing the disease.  The need for further comprehensive assessments for individuals 
with increased risks of developing Alzheimer’s disease, such as genetic testing, is 
imperative in identifying the disease-causing gene mutations associated with the disease.  
These risk factors include increased age, family history, diabetes, hypertension, obesity, 
smoking, depression, cognitive inactivity, physical inactivity, low education, and specific 
genetic markers (APOE-e4).  Focusing efforts in the primary care setting on identifying 
patients who are at increased risk of developing the disease prior to the clinical onset 
allows for the utilization of genetic screening.  Identifying cognitively healthy individuals 
ages 50-75, who are at increased risk of developing Alzheimer's disease related to their 
age or genetic variations in genes, aids providers in diagnosis and clarification of risk for 
those individuals and their families. The current study addressed these issues with an 
emphasis on health promotion that has the potential of long term benefits of extending 
longevity, enhancing the quality of life, and reducing health care cost. 
 
 
Alzheimer’s disease is a significant health problem across the United States.  
There is no standardization in the screening protocol for dementia and its progression.  
Alzheimer’s disease and other types of dementia do not limit themselves to one particular  
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population or socio-economic group.  The disease does not discriminate among culture or 
ethnicity.  Alzheimer’s disease is an irreversible, progressive brain disorder that slowly 
destroys memory and thinking skills and, eventually, the ability to carry out the simplest 
tasks (NIA, 2017). Alzheimer’s is ultimately ta fatal form of dementia.  It is the sixth 
leading cause of death in the United States, accounting for almost 4% of all deaths in 
2014 (CDC, 2017).  The number of Alzheimer's deaths has increased because of the 
growing population of older adults.  The death rate for Alzheimer’s disease increased 
55% from 1999 to 2014.  In 2014, over 93,500 deaths across all 50 states and the District 
of Columbia occurred due to Alzheimer's disease.  Deaths attributed to Alzheimer's 
disease increased among adults 75 years or older.  It is estimated that by 2050, 16 million 
people will be diagnosed with Alzheimer's Disease (CDC, 2017). 
 In 1906, Dr. Alois Alzheimer noticed changes in the brain tissue of a woman who 
has died from an unusual mental illness.  Her symptoms included memory loss, language 
problems, and unpredictable behavior.  After the patient’s death Dr. Alzheimer examined 
her brain and found a multitude of abnormal clumps (now referred to as amyloid 
plaques)and tangled bundles of fibers (now known as neurofibrillary, or tau tangles).  The 
complex disease he discovered became known as Alzheimer’s disease.  Dr. Alzheimer 





specific intervention would successfully treat the problem.  Current treatments focus on 
the management of disease progression and helping people maintain mental function, 
manage behavioral symptoms, and slowing the progression of specific problems, such as 
memory loss.  Researchers hope to develop therapies targeting specific genetic,  
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molecular, and cellular mechanisms so that the actual underlying cause of the disease can 
be stopped or prevented (NIA, 2017).  Research has proven that changes in the brain 
related to the disease process can be present years before symptoms appear.  Evidence 
targets other disease processes that may contribute to Alzheimer's disease, such as heart 
disease, high blood pressure, and high cholesterol.  Early detection of genetic markers 
that are known to be present in Alzheimer's disease could provide the opportunity to 
make changes that could delay or stop the disease progression.  Modifiable risk factors 
such as exercise, diet, and cognitive challenges have been shown to slow or even possibly 
arrest the disease process (CDC, 2017). 
Statement of the Problem 
Alzheimer's disease is a progressive neurological illness that continues to affect 
thousands of individuals annually.  Scientists have identified three genetic markers with 
rare variations related to Alzheimer's disease, along with other genetic markers that are 
known to suggest increased risk; however, these do not guarantee that a person will 
develop the disease.  Investigators worldwide are working to identify additional genes 
responsible for causing Alzheimer’s disease.  As more effective treatment becomes 
available, genetic profiling may become a valuable risk assessment tool for broader use.  
 
 
Genetic screening for APOE-e4, the most influential risk gene, is included in some 
clinical trials to identify participants at high risk for the disease (Alzheimer's Association, 
2019).  Risk factors for the disease include not only age and family history, but also  
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical  
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inactivity, and low education.  These factors are critical components in identifying the 
disease-causing gene mutations associated with Alzheimer's disease. The problem of 
interest in this study was based on whether or not genetic screening was utilized in the 
primary care setting for patients with an increased risk of Alzheimer's disease.  As the  
population ages, the prevalence of the disease will continue to rise.  The cost of 
treatment, long-term care, and caregiver's health maintenance will also continue to rise.  
This cost could potentially put additional strain on the health care system.  
It was predicted that providers in the primary care setting would be confronted 
with barriers to genetic screening.  The barriers included: cost to the patient; insurance 
coverage; education of the population regarding the effects of the disease; lack of time to 
educate the patient in the clinical setting; and lack of staff education and training related 
to the disease.  Review of literature revealed numerous studies that demonstrated the 
early screening of patients with a family history, along with other risk factors such as 
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical 





lifestyle changes that could alter the progression of the disease.  Early intervention could 
be the key to controlling this disease and future research.  
Statement of the Purpose 
The purpose of this study was to determine if genetic screening was being utilized 
in the primary care setting for individuals who were at increased risk for developing 
Alzheimer's disease.  The risk factors which include increased age, family history,  
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diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical 
inactivity, low education, specific genetic markers (APOE-e4) that predispose individuals 
to Alzheimer’s disease. These risk factors can appropriately be identified in the primary 
care setting.  The present study allowed insight into the utilization of genetic screening to 
identify at-risk individuals, and if genetic screening concerning Alzheimer's disease was 
provided in the primary care setting.  Early detection of risk factors related to 
Alzheimer’s disease would provide the opportunity for patients and providers to reduce 
the prevalence and complications of this disease.  Early identification of individuals at 
risk for Alzheimer’s disease, coupled with genetic screening, would decrease the burden 
of effects on concerned individuals and their family members.  Continued education 
related to genetic screening and Alzheimer’s disease is needed for both health care 
providers and individuals with increased risks of the illness like the following: age, 
family history, diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, 
low education, and specific genetic markers (APOE-e4) to stay aware of current 
treatments and resources available.  Research related to genetic testing and Alzheimer’s 
 
 
disease will help to develop an open dialogue among providers and increase awareness of 
the disease and the availability of genetic screening. 
Significance of the Study 
 The significance of this study has proved to be useful to primary care providers, as well 
as neurologists and psychiatric-mental health professionals who diagnose, treat, and 
manage patients with Alzheimer's disease.  While there are no preventive strategies or 
cures for Alzheimer's disease currently, timely diagnosis is essential for effective  
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management.  People are living longer, but the quality of life has diminished significantly 
in the 21st century.  Early detection allows patients and their families the option to modify 
risk factors related to diabetes, hypertension, obesity, smoking, depression, cognitive 
inactivity, physical inactivity, low education, and specific genetic markers (APOE-e4).  
This also allows the patient to receive symptomatic treatment to support lifestyle 
modifications, such as exercise, diet, and cognitive exercises.  Early detection also 
provides the patient the opportunity to make plans for the future.  Extensive research into 
the genetic etiology of Alzheimer's disease has proven that some genetic factors are 
causative and increase a person's risk for the disease.  The need for further 
comprehensive geriatric assessments, such as genetic testing, is a critical component in 
identifying the disease-causing gene mutation associated with Alzheimer's disease.  
Focusing efforts in the primary care setting on identifying patients who are at increased 
risk of developing the disease prior to the clinical onset  allows for the utilization of 
genetic screening.  Identifying cognitively healthy individuals ages 50-75, who are at 





genes, will aid providers with diagnosis and clarification of risk for those individuals and 
their families.   
Conceptual Framework 
Nola Pender's Health Promotion Model was chosen as the theoretical model for 
the current research project because Nola Pender’s model promotes prevention as a 
means of total health and wellness.  She developed her Health Promotion Model, often 
abbreviated HPM, after seeing professionals intervene once a patient developed an acute  
7 
or chronic illness.  She became convinced that the prevention of problems could improve 
a patient’s quality of life and the promotion of healthy lifestyles could save health care 
dollars.  Nola Pender's framework focuses on the positive aspects of health.  The initial 
version of the model appeared in 1982, and a revision of the model in 1996 was based on 
changing theoretical perspectives and empirical findings (Petiprin, 2016).  Nola Pender 
incorporated psychological educational nursing concepts, and theories to formulate the 
Health Promotion Model.  Pender's model stated that people have the capacity for 
reflective self-awareness, including assessment of their competencies.  Self-awareness 
would motivate a positive change and create a desire for the individual to change his 
habits once he is aware of how negative behavior would impact his health.  Pender's 
model emphasizes the conceptual propositions that barriers place constraints on the 
commitment to action.  These barriers would include the cost of healthier food choices, 
association with individuals that use tobacco products and exposure to second-hand 
smoke, or the lack of wellness visits at the appropriate intervals.  For example, an 
individual who is a smoker and obese is educated on risk factors for Alzheimer's disease.  
 
 
With the knowledge provided that smoking and poor food choices increase the 
individual's risk in the development and progression of the disease, it could be inferred 
that the individual would elect to discontinue these activities as an effort to promote his 
health.  Pender's model is based on the concept that education will increase a patient's 
desire to make healthier lifestyle choices and become healthier in body and mind. Once 
the benefits of making lifestyle changes are perceived and barriers removed, the 
individual would then commit to a plan of action to achieve a health-promoting lifestyle.  
                                                                                                                                              8 
           Pender's model concerning Alzheimer's testing in the primary care setting, 
emphasizes that health promotion would allow the choice of wellness rather than 
aggressive disease.  Every patient with increased risk factors, should have the opportunity 
to choose genetic testing.  Genetic testing would enable each patient to have further 
education on the disease.  Genetic counseling, support groups, and online training would 
be considered part of genetic testing according to Pender's concept. 
          Pender's Model would allow everyone to individually determine if socio-cultural, 
economic, or political conditions could affect their health status.  Health care providers 
must be educated in the benefits of early detection so that the general public can be 
knowledgeably informed.  Primary care clinics could also raise awareness about healthy 
behaviors for the general public.  Raising awareness would include health fairs, 
newsletters, and mass media communications to promote community involvement and 
knowledge of the benefits of genetic testing and Alzheimer's prevention.  The current 
study utilized a survey that was  sent via email and social media sites that include primary 





option of genetic screening to patients with an increased risk of Alzheimer's disease.  The 
Health Promotion Model was selected to guide this research because of the model's focus 
on wellness-related health promotion.   
Research Questions 
Two research questions were developed to guide data collection regarding the utilization 





1. Are patients who are at increased risk of developing Alzheimer's disease being 
identified by primary care providers in the primary care setting? 
2.  Are primary care providers utilizing genetic screening for patients who are at 
increased risk of developing Alzheimer's disease?  
 
Definition of Terms 
 For this study, several terms were defined as they apply to this study. The theoretical and 
operational definitions follow, respectively.   
Patient 
Theoretical. Tabor’s defines a patient as one who receives medical care 
Operational. This study defines a patient as a person that is at an increased risk of 
developing Alzheimer's disease. 
 
Increased Risk Factors 
 
 
Theoretical. Tabors define risk factors as an environmental, chemical, 
psychological, physiological, or genetic element that predisposes someone to the 
development of the disease.  
 
Operational.  This study defines increased risk factors of Alzheimer’s disease 
based on guidelines determined by the Alzheimer’s Association.  These increased 
risk factors include not only age and family history, but also diabetes, 
hypertension, obesity, smoking, depression, cognitive inactivity, physical 
inactivity, low education, and specific genetic markers (APOE-e4).  The study  
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Theoretical. Tabor’s defines Alzheimer’s disease as a chronic, progressive, 
degenerative cognitive disorder that causes deterioration in thinking and everyday 
functioning among older adults.  
Operational. This study defines Alzheimer's disease as a chronic, cognitive 
disease that causes debilitating dysfunction to the patient and their family. 





Theoretical. Tabor’s defines the primary care provider as a professional who 
gives health care services or an institution that supervises the rendering of 
such services. 
Operational. This study defines the primary care provider as a Doctor of 
Medicine, Doctor of Osteopathic Medicine, physician’s assistant, or a nurse 
practitioner in a clinical setting who provides health care to patients targeted in 
this study. 
 
Primary care setting 
Theoretical. Medicine.Net defines a Primary health care setting as a patient's 
leading source/setting for regular medical care, ideally providing continuity and 
integration of health care services. 
11 
Operational. This study defines primary health care as the setting in which the 




Theoretical. The National Cancer Institute defines genetic screening as testing 
designed to identify individuals in a given population who are at higher risk of  




Operational. This study defines genetic screening as a blood test used to help 
providers in the primary care setting in Mississippi identify individuals who are at 
increased risk of developing Alzheimer's disease.  
 
Assumptions 
For this study, the following assumptions were made. 
1. The researchers assumed health care providers, in the primary care setting 
(physicians, nurse practitioners, and physician assistants), were to be adequate 
and equivalent educational and professional providers that would be practicing 





2. The researchers assumed that the sample population of primary care providers 
assessed a uniform number of individuals that could be considered at risk for 
Alzheimer’s disease and were familiar with risk factors for Alzheimer's disease. 
 
3. The researchers assumed that the information obtained from this study could be 
obtained by a survey provided through Survey Monkey, a reliable web-based 
survey building company. 
 
Summary of Background 
The explanation for the current study was discussed in this chapter.  Researchers 
sought to determine if providers in the primary care setting were identifying individuals/ 





defined as those with risk factors such as age and family history, diabetes, hypertension, 
obesity, smoking, depression, cognitive inactivity, physical inactivity, and low education. 
All of these are crucial elements in identifying the disease-causing gene mutations 
associated with Alzheimer's disease. The researchers also sought to determine if primary 
care providers were offering and utilizing genetic screening for those individuals/patients 
that were identified with positive risk factors for developing Alzheimer’s. After 
reviewing the literature associated with this ongoing health crisis, it was revealed by 
numerous studies that early testing of patients with a family history or other 
predispositions to the disease, such as hypertension, diabetes, obesity, smoking, 
depression, cognitive inactivity, physical inactivity, low education, and specific genetic 
markers (APOE-e4), could invoke lifestyle changes, such as diet, physical exercise, and 
cognitive exercise could modify the progression of the disease. It was predicted that early  
13 
intervention would be a substantial component in controlling this disease. By directing 
energy toward identifying patients in primary care who are at high risk for developing 
Alzheimer's before the clinical onset of the disease, preferably cognitively healthy 
individuals ages 50-75 with positive risk factors, then the option of genetic testing can be 
pursued. These genetic variations can later be further identified and aid providers with 
definitive diagnosis and interpretation of risk for those individuals and their families.  
Sharing the information collected from this study with primary care providers and the 

















 Identification of individuals who are at risk of developing Alzheimer's disease is of 
utmost importance.  Early diagnosis allows for tailored counseling and care of patients 
and their caregivers.  Providing symptomatic treatment and support also aids patients and 
family members in planning for the future.  The purpose of this study was to determine if 
health care providers in the primary care setting were identifying individuals with 
increased risks for the disease and if genetic screening related to Alzheimer’s disease is 
being utilized in the primary care setting.  Extensive research into the genetic etiology of 
Alzheimer’s disease has proven that some genetic factors are causative and increase a 





such as genetic testing, for those with increased risk factors such as not only age and 
family history, but also diabetes, hypertension, obesity, smoking, depression, cognitive 
inactivity, physical inactivity, low education, and specific genetic markers (APOE-e4) is 
a critical component in identifying the disease-causing gene mutations associated with 
Alzheimer's.  By focusing efforts identifying patients in the primary care setting who are 
at increased risk for developing the disease before clinical onset, opens the door for 
genetic testing. Determining cognitively healthy individuals ages 50-75, who are at 
increased risk of developing Alzheimer's disease-related to their age or genetic variations 
in genes, will aid providers with diagnosis and clarification of risk for those individuals 
and their families.  This chapter introduces the theoretical framework utilized in this 




Theories are an essential guide to the nursing profession.  Nursing theories impact 
the way providers care for patients and maintain the integrity of the profession.  Nola 
Pender, a pioneer in the nursing profession, made a significant contribution to the nursing 
profession as the founder of the Health Promotion Model in 1982.  Pender’s theory/ 
model is used universally for research, education, and practice.  Through revisions and 
evidenced-based practice, this theory has evolved throughout the years to become the 
basis for preventive health measures and the critical function of nurses in helping patients 
prevent illness by promoting well-being and healthy lifestyles.  Health promotion is 
essential for many reasons.  The rising costs of healthcare and improving patient 
 
 
outcomes have become of increasing interest not only to health care workers but also to 
the general public.  The health promotion model focuses on helping individuals achieve 
higher levels of well-being by providing positive resources to help patients make 
behavior-specific changes.  Research has proven with the implementation of the health 
promotion model; patients can prevent illness through their behavior.  In this paper, 
Pender's Health Promotion Theory is thoroughly defined, and a thorough critique of 
research studies utilizing this model will indicate the usefulness of the theory in various 
populations and disease processes. 
Nola Pender defines health as not just being free of disease but includes measures 
taken to promote good health, the individual’s self-perception, and lifestyle.  Pender's 
definition of health is the actualization of inherent and acquired human potential through 
goal-directed behavior, competent self-care, and satisfying relationship with others while  
16 
adjustments are made as needed to maintain structural integrity and harmony with 
relevant environments (Pender, Murdaugh, & Parsons, 2011).  Her definition of health is 
the basis of the Health Promotion Model.  Pender’s theory/ model offers a holistic view 
of the patient, assessing the patient’s history and self-perception to allow providers to 
intervene and form a plan of care accordingly.  The theory is meant to serve as a guide to 
explore complex biopsychosocial processes and motivate individuals to engage in 
behavior that is directed toward the promotion of health (Pender, Murdaugh, & Parsons, 
2011).  This guide allows the health promotion theory to be applied to all populations and 





Nurse practitioners and primary care providers play key roles in developing and 
providing resources for innovative prevention and health promotion programs.  The 
primary emphasis on health promotion has the potential long-term benefits of extending 
longevity, enhancing the quality of life, and reducing health care costs (Pender & Pender, 
1980).  The current study addressed these issues, with a focus on determining if genetic 
screening is being provided in the primary care setting for those with increased risk of 
Alzheimer's disease.  Adding this focus in the primary care setting can allow for early 
detection and identification of those with increased risks of developing Alzheimer's.  
Identification of at-risk individuals provides for timely diagnosis and the availability of 
genetic testing.  Early detection can allow both patients and their families to receive 
effective management, treatment, and support.  It can also provide those with increased 
risks of Alzheimer's disease the opportunity to plan for the future.  Utilization of the 
health promotion model will promote wellness through the use of genetic screening for 
17 
Alzheimer's disease, allowing individuals the choice of wellness by providing genetic 
counseling, support groups, and other resources designated for this disease.   
Review of Literature  
 Brodaty, Connors, Loy, Teixeira-Pinto, Stocks, Gunn, Mate, and Pond (2016.) performed 
a cluster-randomized trial that examined the effectiveness of a peer-led intervention for 
general practitioners to improve the assessment and management of dementia.  The study 
compared the General Practitioner Assessment of Cognition (GPCOG) and the Mini-
Mental State Examination (MMSE) in terms of their ability to detect dementia in primary 
care.  Identifying individuals at risk for developing dementia and Alzheimer’s is often 
 
 
overlooked in the primary care setting.  While a timely diagnosis of the disease is vital 
for effective management, treatment, and support for patients and their families, the 
pressure of time constraints in the primary care setting often makes it difficult to assess 
cognitive decline in this setting adequately.  The MMSE, one of the most widely used 
instruments to test for cognitive deficits, takes approximately ten minutes to perform and 
makes it impractical to use in the primary care setting.  While the GPCOG, also a tool for 
cognitive impairment, was developed to assess cognitive deficits rapidly and only takes 
4-6 minutes to perform.  Data on the effectiveness of this screening tool in the primary 
care setting is limited.  In this study, a sample of 2,028 patients was used to compare the 
GPCOG and the MMSE in their terms of ability to detect cognitive deficits such as 
dementia and Alzheimer’s disease within the primary care setting.  The Cambridge 
Examination for Mental Disorders of the Elderly Cognitive Scale-Revised (CAMCOG)  
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was used as an index for likely dementia.  No theoretical framework was identified for 
this study.  
Brodaty, et al. hypothesized that the GPCOG would perform as well as the 
MMSE to detect deficits in cognitive function or dementia.  The study questioned if the 
GPCOG could be utilized in the primary care setting, in place of the time-consuming 
MMSE with comparable results.  The sample included elderly adults from the primary 
care population aged 75 years or older that had visited their general practitioner in the last 
24 months.  Those with neurological disease, psychotic symptoms, developmental 





patient from completing the study were excluded.  Written informed consent was 
obtained from all patients, general practitioners, and informants to participate.  Each 
participant completed a detailed cognitive screen by trained research nurses, and each 
screening was achieved by utilizing a home visit or a visit to the general practitioner's 
office.  Four instruments were utilized in the baseline cognitive screen.  These four 
instruments included the GPCOG, the MMSE, Geriatric Depression Scale (GDS), and the 
CAMCOG.  The CAMCOG, which uses diagnostic criteria such as memory, language, 
attention, perception, praxis, and executive function to test each patient's cognitive 
function.  The CAMCOG has 59 items covering seven domains and includes the MMSE 
as a subtest.  The highest possible score on the CAMCOG is 104, with anything <79 is 
indicative of dementia.  This instrument was administered first.  The GPOG and GDS 
followed.  The GDS was used to determine if depression influenced the participant's  
performance of the other tools being used in the study.  A 15 item measure was utilized  
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on this scale.  A score >6 indicative of possible depression, with >10 indicating definite 
depression.  The GPCOG consists of two sections; the first section is the patient cognitive 
examination that is scored 0-9.  A score of <5 indicates cognitive impairment, and a score 
of >8 indicates impairment is unlikely.  The second section is an interview with the 
patient's informant.  This section is only given when the patient scores between 5-8 on 
the first section.  The interview section is scored 0-6.  A higher score is indicative of 
better cognition and function.  These two scores are totaled to produce the GPCOG-total, 
a measure of 15.  A cut-point score of 10/11 is likely indicative of cognitive impairment.  
Of the 2,028 participants, 1,717 (84.7%) completed all three relevant instruments 
 
 
(CAMCOG, GPCOG, MMSE) administered in the study.  Of the 1,717 participants, 126 
(7.3%) met the criteria for likely dementia by the CAMCOG screening.  The MMSE and 
GPCOG score on these participants were lower than the participants were older than 
those who did not meet these criteria.  An informant interview for the GPCOG was 
required by 409 of the 1,717 participants.  Analysis of the study's results was assisted by 
McNemar's test to compare sensitivity, specificity, and misclassification rates of the 
GPCOG and the MMSE.  Receiver operating curves (ROC) and Delong's non-parametric 
test was used to allow comparison of the GPCOG and MMSE, including the area under 
the curve (AUC).  Using published cut-points (10/11 for the GCPOG, and 23/24 for the 
MMSE) the GCPOG had greater sensitivity than the MMSE in detection of dementia 
(0.79 vs.  0.51, p < 0.01), though lower specificity (0.92 vs. 0.97, P < 0.01).  The results 
were consistent despite the GPCOG's shorter administration time, indicating the GPCOG 
performs similarly to the MMSE in detecting likely dementia.  The GPCOG and MMSE  
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showed similar sensitivities and specificities across the range of test scores using the 
ROC analysis.  These results suggest possible advantages of using the GPCOG as a triage 
test to identify the increased risk of dementia and Alzheimer's.   
 Despite limitations within the study, it confirms the GPCOG performs similarly to the 
MMSE.  These results make the study very relevant to the current research study for 
several reasons.  Given the MMSE’s administration time is often impractical in the 
primary care setting, the findings of the GPCOG’s performance provides a viable 
alternative for dementia screening.  Time investment is a significant limitation in 





the GPCOG in the primary care setting would increase the likelihood of dementia 
screening being provided.  Positive screening would indicate the need for further in-depth 
assessments by the primary care provider or a referral for further evaluation or 
management.    
The current study will help determine if individuals at increased risk of 
Alzheimer's disease are being identified and if the utilization of genetic testing is being 
provided in the primary care setting for individuals with increased risk for Alzheimer’s 
disease.  Baseline assessments of dementia and cognitive impairment are critical for 
further genetic testing of individuals at risk.  The ability to provide improved risk 
assessments followed up with genetic risk testing will aid in diagnosis and potentially 
clarify risks for the patient and family members affected by the disease.  Nola Pender's 
Health Promotion Model will help guide the current study based on the theory's concept 
and emphasis on health promotion.  This model can be a crucial influence for primary  
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care providers in utilizing genetic testing for individuals and the family members of those 
who are at increased risk for Alzheimer’s disease. 
Evenson, Hoyme, Haugen-Rogers, Larson, and Puumala conducted and reported 
results of their study, in which they sought to learn about the perceptions of outpatient 
internal medicine physicians and their patients regarding genetic testing, to help to inform 
the development of the integration of genetic testing into primary care. As part of a 
program that will progressively integrate genetic testing into primary care, this study's 
results will serve as baseline data about these patients and physicians, which will be 
referred to in future research studies.  Genetic testing is becoming a part of primary care, 
 
 
and the perceptions of both providers and patients are essential to program design and 
development.  Evenson et al. did not indicate a theoretical foundation for their research 
study.  
While Evenson et al. did not clearly state their research questions or hypotheses in 
the article, the purpose of the research focused on learning more about perceptions of 
internal medicine physicians and their patients regarding issues related to genetic testing 
in primary care settings.  Questions motivating the research study included: What is the 
knowledge level of internal medicine physicians about genetic testing in primary care; 
what is the confidence level of these providers about communication with their patients 
about genetic testing; how do internal medicine physicians feel about the roles and uses 
of genetic counselors in primary care; what is the knowledge level of patients of internal 
medicine physicians about genetic testing; what are patients’ perceptions of the 
usefulness of genetic testing; what are patients' concerns about genetic testing?  
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These same questions were utilized in their survey to clarify the scope of the 
research.  This research study took place at 13 primary health clinics in three Midwestern 
states: North Dakota, South Dakota, and Minnesota (Evenson et al., 2016).  Due to this 
study being funded by the University of South Dakota-Sanford School of Medicine, the 
clinics chosen were part of a program they used to integrate genetic testing into primary 
care.  The physicians and patients surveyed came from these 13 clinics.  The researchers 
prepared surveys to allow them to obtain relevant information.  Content experts first 
approved surveys.  After patients visited their internal medicine physicians at one of these 





surveys, 1,000 were distributed.  Only 14% of the patients responded. All 62 of the 
internal medicine physicians at these 13 clinics received web-based questionnaires.  A 
total of 42% (N = 26) of the physicians responded.  The researchers gathered descriptive 
data about the respondents.  Data reported that the patients included age, education, sex, 
race, marital status, location, and income.  For the physicians, descriptive data included 
sex, age, years in practice as a physician, and whether or not they had ordered genetic 
testing in the past six months or ever.  Patient surveys consisted of statements about their 
knowledge of genetic testing, their openness to it, their concerns about it, and their 
perceptions of its value or benefit.  Physician surveys consisted of statements related to 
knowledge of genetic testing and genetic counselors in primary care.  Perceptions of its 
relevance and the physician's level of confidence in communicating about genetic testing 
with patients were also included.  Case studies were also part of the physician 
questionnaires. 
23 
Patients reported knowledge, interest, and openness to genetic testing in primary 
care, as well as concerns about privacy; many patients would prefer to hear about their 
results from a genetic counselor than their physician.  Physicians expressed immense 
knowledge of genetic testing but lower levels of confidence about communicating with 
patients about it.  Implications of this research contribute to the need for ongoing research 
as genetic testing becomes more integrated with primary care; the authors encouraged 
further research. 
Caselli, Langbaum, Marchant, Lindor, Hunt, Henslen, Dueck, and Robert 
conducted a study to determine perceptions from a public viewpoint on genetic testing for 
 
 
Alzheimer's disease.  They sought to answer questions based on the desire for genetic 
testing, the reaction to results once testing was concluded, and the knowledge of those 
results concerning the disease process.  Alzheimer's disease is very prevalent, and it is 
believed to increase the susceptibility of inheritance if positive for the apolipoprotein E 
(APOE) genotype.  Carrying this genetic makeup poses the most considerable risk of the 
development of the disease.  However, with no known cure for this disease, providers 
have difficulty with the management of pre-symptomatic testing of Alzheimer's and the 
proper way to disclose this information to patients.  While direct-to- consumer marketing 
can be a positive resource to some of the population, screening, counseling, and follow-
up with consumers is unlikely to occur once purchase is made.  However, if genetic 
testing for Alzheimer's disease was provided in a primary care clinic with a trusted health 
care provider on individuals who are likely to seek testing, then screening, counseling, 
and follow-up visits could be scheduled and carried out.  The researchers designed a  
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questionnaire to assess the following: "the desire for preclinical testing in the absence of 
effective interventions, the possible reactions to such information, and how well the 
results of such testing would be understood."  The researchers developed a questionnaire 
containing a series of yes/no and multiple-choice questions.  Portions of this 
questionnaire determined the patient's demographics.  This included age, sex, race, 
education, a first degree relative with Alzheimer's disease and other family affected, 
caregiver experience, and if the individual resided in an area where they were not raised.   
The questionnaire proceeded to ask questions about disease perception.  It 





separated those who were only in agreement when it was covered by insurance.  It 
determined the individuals' support system, and it revealed how those who hypothetically 
tested positive would react.  These options included: live a healthier life, invest in long 
term care insurance, spend all money for pleasure or consider suicide.  The survey also 
asked two multiple-choice questions to determine the knowledge of the respondent 
concerning their potential positive genetic results.  The researchers proceeded to post the 
survey on the Alzheimer's Prevention Registry website.  The survey was available online 
with site visitors who registered on the website between November 1, 2012-June 30, 
2013.  Those registered with the Alzheimer's Prevention Registry must be over the age of 
18 and interested in the development of new research for Alzheimer's disease for personal 
knowledge development or to be a potential candidate in future research studies related to  
Alzheimer's disease. A total of 4,036 surveyors participated in the research study.  The 
researchers used descriptive statistics that included the evaluation of continuous and  
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categorical data.  The continuous data were analyzed using unpaired t-tests and univariate 
regression and presented using mean +/- standard deviation.  The questions on the survey 
were defined as the independent variable.  The participants were defined as the dependent 
variable.  The survey included the opinion of genetic testing, isolated those interested in 
genetic testing, and determined the reaction of the results from the genetic testing.  The 
two multiple-choice questions to determine the participants' knowledge of 
presymptomatic genetic testing of Alzheimer's disease for each of the previously 
mentioned demographic variables were analyzed using this method.  Also, the categorical 
data were analyzed using chi-square and multivariate analysis and presented using 
 
 
frequency.  This information included the eight demographic variables that were 
evaluated using odds ratios and 95% confidence intervals.  Once the data was analyzed, 
the researchers determined a strong desire for pre-symptomatic genetic testing for 
Alzheimer's disease among individuals.  Of the participants, the mean age was 45-80, 
while the mean education was 12-20 years.  Eighty-two-point, one percent of participants 
were women, and well over half the respondents reported having a first degree relative 
with an Alzheimer's diagnosis.  Seventy-eight-point three percent of the surveyors 
believed they were at a higher than average risk of developing Alzheimer's disease at 
some point in their life. The survey asked participants their most significant disease 
related fear, and 82% of participants selected Alzheimer's disease over a heart attack, 
stroke, or cancer.  With knowledge of no cure for the disease, 70.4% of participants felt 
genetic testing being offered was imperative. However, 80.8% of participants would elect 
to have presymptomatic genetic testing if insurance coverage was offered, while only  
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58.7% would elect for testing with a minimum of $100 out of pocket cost.  The 
participants were also asked how they would respond to possible positive genetic results. 
Of those asked, 90.5% stated they would commit to a healthier lifestyle, which correlated 
with the individual's education level. In contrast, 76.3% of individuals would seek to 
obtain long term care insurance if they had not already, which correlated with age and 
male gender.  Of the surveyors, 18.4% responded to these possible results by choosing to 
live the rest of their life to the fullest and spend all of their earned money, which 
correlated mostly with the racial background of white, non-Hispanic individuals.  The 





genetic results that correlated with education.  Lastly, the multiple-choice questions were 
listed to assess the knowledge of the individuals.  The researchers asked about the 
outcome of an APOE e4 Alzheimer gene carrier with no current signs and symptoms of 
Alzheimer's disease.  Of the participants, 86.9% were able to correctly identify that this 
carrier was at an increased risk for Alzheimer's disease. Still, it did not currently 
determine the existence of the disease in the individual.  However, of the participants, 
only 32.6% were able to determine the existence or increased risk for diagnosis of 
Alzheimer's disease when associated with a positive biomarker test, such as an amyloid 
PET scan, and mild cognitive delay.  From this study, the researchers determined that 
much more education regarding presymptomatic genetic testing for Alzheimer's disease 
is needed.  The researchers also determined that those who had a positive family history 
of Alzheimer's disease were more fearful of the development of the disease themselves 
and were more likely to proceed with genetic testing.  However, most individuals stated t 
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they would be willing to talk with someone, such as a health care provider or family 
member if they were to test positive for the APOE genetic marker.  The researchers 
determined that psychological evaluation and genetic counseling should be ensured 
before the information is revealed to individuals who chose to participate in any genetic 
testing, especially those that currently are without a cure like Alzheimer's disease.  They 
also determined that genetic testing can be beneficial for some, such as easing worry in 
those who are low risk or allowing those that are of high risk to participate in a healthier 
lifestyle as a preventative measure.  A recommendation for future research within this 
article would be to expound on the compliance of positive lifestyle changes concerning 
 
 
prognostic testing for this disease.  This article supports the student nurse practitioners' 
research on The Utilization of Genetic Testing in the Primary Care Setting for Individuals 
with Increased Risk of Alzheimer's Disease through determining the interest of the public 
population in genetic testing for Alzheimer's disease.  It determines the desire for testing 
and assesses the public understanding of the testing.  With such an increase in direct to 
consumer genetic testing offered without any follow-up care, genetic counseling, or 
provider recommendations on a disease process that has limited therapeutic options and 
no cure, this study supports the idea that this genetic testing should be offered in a 
primary care setting where the provider can disclose results and can offer memory 
enhancing medications, genetic and psychiatric counseling, and emotional support.         
Huang, Huston, and Perri conducted a research study that sought information 
regarding the preferences of consumers in the United States regarding predictive genetic 
testing for Alzheimer's disease (AD), to help to inform health-care providers,  
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policymakers, and developers of genetic testing.  In the United States, Alzheimer's 
disease is currently the sixth most common cause of death.  With the population aging 
and the prevalence of Alzheimer’s disease increasing, researchers need to gain 
knowledge about the disease and patient’s perceptions and attitudes about genetic testing 
(Huang et al., 2014).  Specifically, learning how individuals decide on whether or not to 
undergo predictive genetic testing for Alzheimer’s disease will help health-care providers 
and policymakers.  Huang et al. referred to this study as a “rating conjoint study,”  based 
on Lancaster’s consumer theory.  This theory serves as the framework of this study using 





various characteristics or attributes (Huang et al., 2014).  Huang et al. (2014) stated their 
research question for the study clearly.  What characteristics of predictive genetic tests 
for Alzheimer's disease do consumers in the United States find to be the most important 
when deciding whether or not to undergo this predictive testing?  Hypotheses were not 
articulated in the article. In this study, the three factors that were rated and analyzed were 
predictive value, treatment availability, and anonymity.   
Through Qualtrics, the researchers distributed an anonymous online survey using 
conjoint analysis to a panel from the general population (Huang et al., 2014).  The survey 
went through three rounds of pre-testing before the final survey phase of the study.  The 
only inclusion criterion was that respondents had to be adults between the ages of 18 and 
64.  Twelve scenarios regarding predictive genetic testing for Alzheimer’s disease were 
presented to the respondents, who rated the scenarios by answering 17 questions on an 
11-point scale.  They also answered open-ended questions about what dollar amount they  
29 
would be willing to pay for the genetic testing related to Alzheimer’s disease in each 
scenario.  The scenarios each contained different aspects of the three variables: predictive 
value of the genetic test, treatment availability for Alzheimer’s disease, and anonymity. 
Over four days, a total of 295 participants responded online.  The researchers collected 
these responses (N = 295).  Descriptive statistics regarding the respondents indicated that 
their mean age was 44; 86% of the respondents were white; 39% held at least a bachelor's 
degree; 53% had annual household incomes of $50,000 or less; there were equal numbers 
of male and female respondents. Regarding Alzheimer’s disease, in this sample, 15% of 
 
 
respondents had a family member with the diagnosis of Alzheimer’s disease, and 16% 
had served as caregivers for someone with the disease.  
Huang et al. analyzed the results of the survey and found that the most important 
of the three factors was accuracy, rated to be of top importance by 64% of the 
respondents.  Treatment availability and anonymity represented 21% and 15% of the 
respondents’ preference ratings.  The most preferred scenario was a genetic test for 
Alzheimer’s disease that would be 100% accurate, with a cure available for Alzheimer’s 
disease and anonymous test results.  Respondents indicated that they would accept a test 
that had 80% accuracy if a cure for the disease was available.  Regarding their 
willingness to pay for the test, 12.9% indicated that they would not be willing to pay for 
any of the scenarios. Of those respondents who did indicate a willingness to pay, they 
noted that they would pay $100 for the test in the most preferred situation. All scenarios 
with 100% accuracy had the highest willingness-to-pay results, while those scenarios 
with as low as 40% accuracy always showed the lower willingness-to-pay results.   
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Implications of the study include the importance of certainty of predictive genetic tests to 
consumers.  The authors suggested future research studies using samples that are more 
representative of the general population, as well as future research on consumer 
preferences as treatment options and predictive value of genetic testing for Alzheimer’s 
disease continue to improve (Huang et al., 2014). 
This research identifies the preferences of genetic testing related to Alzheimer's 
disease and recognizes the benefits of utilizing this testing in the primary care setting.  It 





testing. This consumer research study helps give an insight into how patients in the 
current study will perceive testing.  
Wollam, Weinstein, Saxton, Morrow, Fowler,  Suever-Erickson, Roecklein, and 
Erickson performed a neuropsychological evaluation and consensus to determine if the 
genetic risks of processing multiple risk alleles associated with Alzheimer's disease can 
be a predictor of increased risk of late-life cognitive impairment.  Alzheimer's disease 
(AD), being the most common cause of irreversible dementia, continues to grow in 
prevalence and public health impact, according to both the National Institute of Health, 
and the National Institute of Aging, and Human Services Department.  Research on the 
genetic etiology of Alzheimer's disease has provided knowledge of some genetic factors 
that are causative and increase the risk of the disease.  While family history is a 
significant risk factor for Alzheimer's disease, other genetic variants have been identified 
as risk factors for cognitive decline. These variants include Brain-Derived Neurotrophic 
Factor (BDNF), Catechol-O-Methyltransferase (COMT), and Apolipoprotein E (APOE).   
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In this study, with a sample of 95 older adults, a genetic risk score was constructed based 
on the accumulation of these genetic alleles/variants. Identification of these variants in 
the primary care setting will provide improved significant risk estimates to individuals 
based on the presence of one or more susceptibility gene alleles. No theoretical 
framework was identified for this study.  
Wollam, et al. identified the hypothesis for this study by the prediction that a 
higher genetic risk score would correspond to an increased risk of cognitive impairment.  
By studying target gene variants (genotypes), candidates with increased genetic risks 
 
 
allowed for a genetic risk score to be assigned.  APOE, which identifies a clear link to 
Alzheimer's Disease; BDNF and COMT, which both have essential roles in brain 
functions in late adulthood, were targeted to investigate how multiple gene influences can 
be aggregated into a single risk profile to predict the prevalence that could predispose 
individuals to Alzheimer's Disease.  The testing of the combination of these three high-
risk genotypes would be predictive of late-life cognitive impairment.    
The study utilized data and sampling methods that were collected as part of more 
extensive research examining the utility of providing cognitive testing in older adults in 
primary care physician (PCP) offices.  Risk factors for late-onset Alzheimer' Disease 
identified by the Genome-Wide Association Studies (GWAS) were used to guide this  
study.  The study was conducted in the offices of eleven primary care providers in greater 
Pittsburgh and surrounding areas.  The parental study included 109 participants that were 
recruited based on the criteria of being 65 years or older, no medical chart diagnosis of 
dementia, no acute illness, and permanent residence was not a nursing home facility. Of  
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the 109 Participants that provided consent through the University of Pittsburgh 
Institutional Review Board before beginning the study, five were excluded initially.  The 
exclusions were related to incorrectly recorded data and allelic frequency differences 
between races.  Nine additional exclusions were made after the study began, related to 
missing genotype information from one or more genes. 
Each participant completed a comprehensive neuropsychological test panel 
assessing five cognitive domains: memory, executive function, spatial ability, language, 





determination of the cognitive status.  Cognitive status was classified as normal, mild, 
cognitive impairment (MCI), or dementia. These classifications were based on the 
University of Pittsburgh Alzheimer's Disease Research Center.  With the final diagnosis 
taking into account, cognitive test scores, as well as demographics, functional, 
behavioral, and medical information.  Adjudications were conducted blind to the study 
group status of the parent study.  Genomic DNA was collected from each participant 
using the Orange-DNA Self Collection Kit and processed according to laboratory 
protocol from Orange-DNA. Each individual participant was genotyped for BDNF 
(rs6265), COMT (rs4680), and APOE( ApoE2, ApoE3, ApoE4).  Individual genotype  
group analysis was also performed.  These particular groups consisted of BDNF genotype 
group-Val homozygotes, Valheterozygotes, or Met homozygotes; COMT- Val 
homozygotes, Val heterozygotes, or Met homozygotes; and APOE- E2/E3, E2/E4, 
E3/E#, E3/E4, or E4/E4.  The genetic score risk was computed by summing up the 
presence or absence of each genotype.  A "0" was assigned for each genotype with  
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minimally associated genetic risks with cognitive deficits or a "1" for acknowledged 
association with cognitive deficits.  A risk score was summarized from these three-
component risk genotypes.  The sum with genetic risk values scored between 0 and 3 was 
assigned.  The value of "0", the absence of any genetic risk genotypes represent the 
lowest genetic risk category for the decline of cognitive status;  "1" represents testing 
positive for one risk genotype, "2" represents the positive test for two risk genotypes, and 
"3" represents possession of all three risk genotypes.  The number "3" is also 
representative of the highest genetic risk category for the decline in cognitive status.  
 
 
Demographic variables, such as age, gender, and years of education, were also included 
in this analysis. 
Analysis of the collected data determined that the hypothesis was statistically 
supported.  Hierarchical logistic regression analyses were used to determine if any of the 
three genotypes were individually predictive of cognitive status.  A genetic risk score was 
created to represent the accumulation of risk genotypes, such as BDNF, COMT, And 
APOE.  The demographic variates were used to isolate the effects of the genotypes and to 
test whether the risk score predicted the presence of late-life cognitive impairment.  The 
conclusions were, after controlling variations from age, gender, and education, the APOE 
carrier status was predictive of an increased risk of cognitive impairment (OR=3.561, 
P=0.032, and 95% CI=1.116,11.365).  Neither BDNF or COMT genotype was related to 
cognitive status (BDNF, OR=1.149, P=0.755, 95% CI=0.479, 2.759;  COMT OR= 1.074, 
P=0.808, and 95% CI=0.606, 1.903).  The results were consistent with the hypothesis; the 
higher the genetic risk score significantly predicted, the higher the risk of having  
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cognitive impairment.  The study proved a nearly 4-fold increase of cognitive impairment 
for sample participants with increased genetic risk scores and individual gene 
polymorphisms as covariates (OR=3.824, P=0.013).  These findings support the use of a 
single genetic risk score to represent the accumulation of genetic influences affecting 
cognitive and brain health concerning Alzheimer's disease. 
The study is relevant to the current research study for several reasons.  The 
effectiveness of genetic risk scores and the potential to use these scores as predictors in 





individuals who are at risk.  The current study will help determine if the utilization of 
genetic testing is being provided in the primary care setting for individuals with increased 
risk for Alzheimer's disease.  The ability to provide improved risk assessments to 
individuals based on the presence of one or more multiple genotypes will aid in diagnosis 
and potentially clarify risks for the patient and family members affected by the disease.  
Nola Pender's Health Promotion Model will help guide the current study based on the 
theory's concept and emphasis on health promotion.  This model can be a crucial 
influence for primary care providers in utilizing genetic testing for individuals and the 
family members of those who are at increased risk for Alzheimer's disease.  
Shinya Tasaki, Chris Gaiteri, Vladislav A. Petyuk, Katherine D. Blizinsky, Philip 
L. De Jager, Aron S. Buchman & David A. Bennett conducted a research study to access 
genetic influence on motor impairment through a case study of older adults and 
established critical molecular pathways that could mediate the risk. The study was 
motivated by the increasing evidence of Alzheimer's disease, which impacted late-life in  
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both cognitive and motor functions.  Genetic variation was claimed to have a significant 
impact on the development of Alzheimer's dementia as well as declined cognitive. The 
data examined for this study were brain multi-omics, including DNA methylation, 
transcriptome, histone acetylation (H3K9AC), and targeted proteomics and diverse 
neuropathology.  The source of the data for this research, as stated, was gathered from a 
total of 552 aged individuals who had at least four out of five omics measurements from 
DLPFC.   No specific theoretical framework was adopted for this study. Research 
questions and hypotheses for the study are identified.  The questions that were formulated 
 
 
in this research were: What is the genetic risk for Alzheimer's dementia influenced motor 
functions in older adults?  What are the biologic factors linking the genetic risk for 
developing Alzheimer's dementia with motor impairment molecules and brain 
pathologies explaining most genetic effects?  The researchers sought to establish the 
relationships between genetic risk variants for AD and motor functioning in older adults.  
This study was carried out in the Rush Alzheimer's Disease Center (RADC) in 
Chicago and employed two longitudinal, community-based aging studies that contained 
various harmonized data measures, which are collectively termed as ROSMAP.  The 
ongoing studies that the research targeted the older population shows that there is a high 
genetic risk for AD variants and motor functioning.  The researchers employed a sample 
of more than 3,600 older persons who agreed to annual brain donation evaluation as well 
as motor testing.  A total of 1885 participants completed the genotyping and motor 
assessments by March 2018.  A certified board of neuropathologists reviewed and 
approved the brain autopsies.  The study excluded individuals who had cognitive  
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impairments but without dementia.  Several parameters included motor functions, 
Parkinsonism score, motor score, neuropathology indices, omics measures, and PRS.  On 
the motor assessment function, two related phenotypes validated in previous studies and 
without correlation were examined.  The global Parkinsonism signs were estimated 
within a score of 0 to 100 across each domain.  Neuropathology indices were also taken 
and described in supplementary methods and a complete list of brain pathologies 
assessed.  Omics measurements for 7,159,943 single-nucleotide polymorphisms in 2093 





genome-wide association study data from IGAP and GWAS.  The dependent variable 
was the Alzheimer's dementia motor deficits, while the independent was the genetic 
factors assessed by the researchers. As stated in the study, “the statistical analyses done 
involved linear or logistic regression models for testing the association for continuous or 
categorical outcomes, respectively.”  Demographic variables were dropped with the use 
of a linear model, leaving residuals for use in establishing the association.  The residuals 
were left to test the association at age, sex, years of education, and the first three 
genotyping principal genotyping components (PCs), giving an account for possible 
stratification within the population.  Other analyses were bioinformatic analyses for 
evaluation of the AD-PRS effect on motor function.  The analysis showed that there were 
associations within global Parkinsonism and global motor scores when AD-PRS was 
based on IGAP at an SNP threshold of p<0.5. PD-PRSs was also calculated to examine 
whether the genetic risk for PD explained variances of motor dysfunction in older adults.  
In this study, they did not correlate with motor scores but moderate with Parkinson's  
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disease.  The overall results implied that Alzheimer’s disease influenced motor functions 
in older adults meaning that cognitive and motor impairment share at least a part in the 
genetic architecture.  Testing for possible biological factors connecting to genetic risk for 
Alzheimer’s disease with motor impairment showed that brain pathologies explain most 
of the genetic effects. The results for this study are useful to the bodies identified by the 
researchers in that they will be employed in gauging whether they corresponded to those 
of past studies in the same area. Further suggestions from this study are to establish 
whether there are genes responsible for impairment lying outside of genes supported by 
 
 
genome-wide significant loci. Various factors that are assessed through the use of 
multiple research tools make this study beneficial to the current research. The research 
provides a strong basis for building research as it allows for an in-depth insight into how 
the research was conducted.   The study shared evidence that the evidence of Alzheimer's 
disease caused impacts in late-life in both cognitive and motor functions.  Genetic 
variation was proven to have a significant effect on the development of Alzheimer's 
dementia as well as declined cognitive function.  This finding can prove to be valuable 
information for the current study to assess the genetic influence on motor impairment in 
older adults.  Yokoyama, Bonham, Sears, Klein, Karydas, Kramer, Miller, and Coppola 
conducted a study to determine the reliability of an assessment that observed multi-
variant heritable probability on a group of phenotypically heterogeneous individuals with 
a current Alzheimer's disease diagnosis. This research study was conducted based on 
population growth and the medical advances that have allowed individuals to live longer 
lives. However, as the population ages, the incidence of Alzheimer's disease increases.   
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Because of the increase in Alzheimer's diagnoses, identifying the individuals at most 
significant risk for the development of this neurodegenerative disease is imperative.  The 
researchers divided Alzheimer's disease into two categories: the patients who present 
with amnestic clinical findings and the patients who present with atypical clinical results.  
Those with amnestic syndromes will present with common findings of progressive 
memory loss and cognitive impairment.  The individuals with atypical clinical outcomes 
will present with posterior cortical atrophy that affects visual processing,  primary 





symptoms that affects the emotional and reasoning ability of the individual.  Due to the 
variation of the disease process, determining genetic variants has proven difficult for 
genetic analysis.  However, it is estimated that the heritability of Alzheimer's disease is 
around 74%, with the e4 allele of apolipoprotein E (APOE) being the most significant 
risk factor of the potential diagnosis.  This information inspired the researchers to view 
the disease from a multi-locus approach in order to "increase the ability to identify 
individuals at highest risk for Alzheimer's disease syndrome."  The investigation that took 
place in this research study involved two approaches to determine the polygenic risk or 
probability of the presence of heterogeneous Alzheimer's disease.  One approach created 
and reviewed the credibility to predict Alzheimer's disease through the use of a multi-
marker genomic risk score.  A discovery associate study had the purpose of reproducing 
previous findings related to the disease and observing other variations associated with the 
risk of disease in participants. The second approach used a decision tree analysis that 
presented the variables and relations between the variables to calculate the result.  This  
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calculation allowed them to determine demographic risk factors and hereditary risk 
factors that could lead to the development of Alzheimer's disease.  The researchers 
sought to determine the factors and the interactions between variables that allowed them 
to make an educated prediction on individuals who will develop Alzheimer's disease.  
Because other research studies determined the APOE genetic marker was the primary 
genetic contributor of the disease, the research studies sought to confirm or deny this 
finding and determine other significant genetic markers as well.  
 
 
This research study is a quantitative, quasi-experimental study.  The dependent 
variable in this study was identified as the participants of the research study, while the 
independent variable was the genetic analysis.   It was conducted through the first 
selecting participants.  The individuals ranged from 65-101 years old and agreed to be 
subject to genotype analysis. The individuals evaluated could not be related and were 
made up of Caucasian males (n=216) and females (n=232). Informed consent was 
received from all participants, and approval was granted from the UCSF Institutional 
Review Board. The participants then underwent a clinical assessment and were evaluated 
through a neurological exam, a cognitive assessment, and assessment of any medical 
history. Participants in this study had a partner, such as a friend, spouse, or child that was 
assessed to determine functional capabilities and was their source of support throughout 
the study. The team consisting of a neurologist, neuropsychologist, and a nurse 
established diagnoses through referring to "consensus criteria for Alzheimer's disease." 
Atypical Alzheimer's disease diagnoses were also determined, such as logopenic variant 
PPA, PCA syndrome, primary executive Alzheimer's disease, vascular disease, and  
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dementia with Lewy bodies.  Controls in this study were identified as the Mini-Mental 
State score of at least 26 or scoring of 0 on the Clinical Dementia Rating Scale. Controls 
also included the participants to have no report of the decline of cognition within the 
previous year and could not have shown evidence of a neurodegenerative disorder when 
observed by the neurological team.  If any of these was observed, then the individuals 





DNA samples were extracted from the participants through a peripheral blood 
sample.  These samples were genotyped along with 75 variants to determine the 
association with an increased risk of Alzheimer's disease. The 75 variants were 
determined through observation of previous research studies used to assess the utility of 
genes involved in "neurodegenerative disease, neurodevelopment, social function, 
behavior, neuropsychiatry, language on diseases like Alzheimer's disease and 
frontotemporal dementia.”  The risk scoring was ranked by p-value.  The single-
nucleotide genetic variations were removed where the alleles presented with the non-
random linked association.  The unlinked markers were used to create a scoring set. This 
scoring set algorithm was implemented using a valid genotype/phenotype analysis toolset 
to determine its predictability.  This process was done to determine both the discovery 
and validation cohorts.  The decision tree analysis was then determined using stopping 
rules.  These included "when subgroup totals were less than 10, when a significance 
value corresponding to a multiple-testing corrected x^2 test greater than p=0.01 was 
reached, or when a three-way interaction was reached."  These results allowed for the 
analysis of control groups and all participants.  There was also an analysis of control  
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groups compared with atypical Alzheimer's disease and separately with amnesic 
Alzheimer's disease.  Added predictors consisted of gender, age, and all genetic variants 
with random association alleles.  These predictors allowed for genetic variations to be 
determined and linked to the development of Alzheimer's disease. 
Outcomes of the study determined that the best predictor of Alzheimer's disease 
was found by repeatedly generating variants until a risk score panel was developed that 
 
 
was composed of 17 of those variants.  When the APOE genetic marker for Alzheimer's 
disease was evaluated independently; it did not reveal a significant prediction value when 
compared with the controls.  However, in the discovery cohort, the 17-marker risk score 
identified the clinical significance of the AUC genotype. It concluded that this marker 
was superior to determine the genetic susceptibility of AD than the APOE alone.  In the 
validation cohort, this did not provide the same outcomes.  In this cohort, there were no 
other genetic variants that determined susceptibility better than the APOE genetic marker. 
When analyzing all cases of Alzheimer's disease among the participants, being a carrier 
of the APOE genetic marker was the "first differentiator of cases from controls."  Other 
predictions of genetic risk were determined to be greater than or equal to 77 years old, 
being a carrier for any of the minor alleles, and being homozygous for the dominant 
allele, ATP2C2, that controls language traits, such as dyslexia.  Because this model used 
these predicting factors, it was able to diagnose Alzheimer's disease 87% of the time 
correctly.  This study determined that the APOE genotype was the superior predictor of 
Alzheimer's disease.  It also suggested that "phenotype variability in the disease 
complicates simple genetic risk modeling, particularly when co-morbidities are  
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suspected," meaning those with atypical Alzheimer's disease were more challenging to 
predict. However, other studies have been conducted to suggest that atypical Alzheimer’s 
disease is more heritable than amnesic Alzheimer’s disease.  The researchers 
recommended a whole-genome association study in the future with more varied 
participants with specific atypical phenotypes.  This study could determine differently 





specificity in studies of amnestic Alzheimer’s disease may also provide statistical power 
to identify risk factors of small effect size.”  
This research study is beneficial in the APRN students’ research project on 
Alzheimer’s’ disease and genetic testing. It allows for a more genetic viewpoint on the 
idea of genetic testing for Alzheimer’s disease.There are so many variations of genetic 
make-up concerning this disease that it is imperative to determine which of these variants 
will provide the most reliable outcome of an individual's genetic risk.  This research 
study delves into the scientific side of genetic testing and displays the probability of 
which genetic marker best determines the development of Alzheimer’s disease.  In 
determining the specific variation of Alzheimer's disease, whether atypical or amnestic, a 
physician can determine which genetic testing should be done.  APOE genotype is the 
best predictor of risk for genetic susceptibility among individuals; however, considering 
the variation of the disease process, amnestic and atypical Alzheimer’s disease can have 
“differential genetic risk factors which can account inaccuracy of the traditional 
polygenic scoring method.”  Determining those at highest risk of the disease through 
being informed on the specific type or variants of genetic markers can allow earlier i 
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identification and intervention.  This data creates the opportunity to provide clinical 
understanding and provide support before the development of symptoms of Alzheimer’s 
disease.   
A detailed review of literature specific to research related to Alzheimer's disease 
and genetic screening serves the current study well as a guide to promoting the need for 
further research in this area.  The proven research from these studies can be used to direct  
 
 
strategies to help improve the quality of life for individuals and their families who are or 
will be affected by Alzheimer’s disease. Primary emphasis on health promotion that 
includes extending longevity, enhancing the quality of life, and reducing health care cost. 
The current study addresses these issues, with a focus on determining if genetic screening 
is being provided in the primary care setting for those with increased risks of Alzheimer's  
disease.  Identification and early detection of Alzheimer's disease provide the opportunity 
for genetic screening that can provide patients and their families the opportunity to 











Because of the increased occurrence of Alzheimer’s disease within the United 
States, the researchers sought to determine if the utilization of genetic testing was being 
provided in the primary care setting for individuals with increased age, family history, 
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical 





patients at an increased risk for developing Alzheimer's disease. Because Alzheimer's 
disease carries such a strong genetic correlation, the researchers hoped to bring awareness 
to the importance of genetic testing and encourage providers to consider the avenue of 
genetic testing in their practice in order to allow for preparation and health promotion 
among the at-risk population.  The researchers sought to determine if genetic testing was 
being conducted by primary health care providers throughout the state of Mississippi.  
Design of the Study 
A quantitative survey was used as the design in this study, and was appropriate 
for the study to determine if primary care providers were utilizing genetic testing on 
individuals with an increased risk of developing Alzheimer’s disease based on 
Alzheimer's Association guidelines.  Alzheimer’s Association guidelines determine risk 
factors for the disease to include not only age and family history, but also diabetes, 
hypertension, obesity, smoking, depression, cognitive inactivity, physical inactivity, low 
education, and certain genetic markers (APOE-
e4).   
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Setting of the Study 
 The survey was sent electronically to clinics of various settings across the state of 
Mississippi.  These various settings included primary care clinics, urgent care clinics, and 
specialty clinics.  Primary care providers of different credentials were displayed, 
including Doctors of Medicine, Doctors of Osteopathic Medicine, Nurse Practitioners, or 
Physician Assistants.  The participants were selected at random and represented both 
 
 
urban and rural areas of the state of Mississippi. The survey was also shared on a private 
Facebook group of Mississippi Advanced Practice Registered Nurses consisting of 1,700 
members.   
Population and Sample 
 A convenience sample was utilized for this study. The population of the study 
included men and women of all ages that presented with increased risk factors for 
developing Alzheimer’s disease based on the guidelines put forth by the Alzheimer’s 
Association.  This population was relevant to the study in that age alone does not define 
the risk for the development of this disease.  Alzheimer’s Association guidelines state 
risk factors for the disease include increased age, family history, diabetes, hypertension, 
obesity, smoking, depression, cognitive inactivity, physical inactivity, low education, and 
certain genetic markers (APOE-e4).  Because of the active genetic link related to 
Alzheimer's disease, individuals with a family history of the disease are at an increased 
risk of exhibiting symptoms of Alzheimer's disease at some point in their life.  This 
survey determined if genetic screening was being offered to these individuals by their 
primary care providers.  This information allowed education opportunities for providers  
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and promoted the maintenance of cognitive health for maximum longevity among 
patients. Electronic surveys were sent out to varying primary care providers through a 
reputable survey building website. 
Methods of Data Collection 
After obtaining consent from Mississippi University for Women's Institutional 





providers across the state of Mississippi.  The researchers created a survey using a 
reliable survey building website, Survey Monkey, Inc. (see Appendix B).  These surveys 
served as data collection tools and assisted in determining if providers were able to 
recognize those at risk for developing Alzheimer's disease based on the Alzheimer's 
Association guidelines.  The survey also asked questions to determine if those at risk 
were being educated and offered genetic screening.  The survey began by stating the 
intent of the survey and obtaining the consent to participate.  It followed with a statement 
of privacy, ensuring that no information regarding participants or affiliated clinics would 
be revealed.  The survey was used to collect demographic data to determine the 
credentials of the primary care provider (nurse practitioner, physician’s assistant, or 
medical doctor) and their specified area of employment.  It followed with questions to 
determine if primary care providers were assessing the patient for risk factors that would  
place them at an increased risk of developing Alzheimer's disease. It then determined if 
genetic screening was being offered to the individuals that were at an increased risk.   
These surveys were sent electronically to primary care providers across the state of 
Mississippi. The survey was also shared on a private Facebook group of Mississippi  
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Advanced Practice Registered Nurses consisting of 1,700 members. The surveys did not 
reveal any protected health information or have any patient identifiers. There were also 
no participant identifiers as not to skew the research study.    
Methods of Data Analysis 
  Upon completion, data collected was deciphered, evaluated, and compiled.  The website, 
Survey Monkey, Inc., initially compiled the data. The data was then released to a 
 
 
reputable statistician who analyzed and parsed the data using chi-square tests to 
determine significance. The results were transferred and displayed using varied forms of 
charts and graphs.  All data and research results were shared with the Mississippi 
Alzheimer's Association research group in hopes of educating providers on the 
importance of genetic screening for this disease. 
Instrumentation 
  The electronic survey was completed using Survey Monkey, Inc., a reliable survey 
building website.  It compiled all the data and preserved it securely until the collection 
process was completed.  The survey consisted of a series of questions developed by the 
researchers.  Questions included demographic data, provider assessments, evidence 
regarding genetic screening being offered, specific cognitive assessment utilized, reasons 
genetic screening was not utilized, and the selection of follow-up care provided.  The 
questions were answered by each provider participating in the survey.  The surveys were 
sent electronically to various primary health care providers across the state of Mississippi 
to determine whether genetic screening was being offered to individuals considered at-
risk for developing Alzheimer's disease.                            
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The survey consisted of multiple-choice questions, with three of those being 
“select all that apply” questions.  The survey began by stating a right to privacy and 
ensuring that no information regarding participants or affiliated clinics would be revealed 
through participation in this survey.  Questions 1 and 2 determined the demographic data, 
including the credentials of the primary health care provider (Doctor of Medicine, Doctor 





clinic of affiliation (primary care, urgent care, or specialty clinic).  Questions 3 and 4 
were related to the research questions and determined if providers were aware of 
Alzheimer’s related risk factors and if they were routinely assessing these risk factors. 
Question 5 and 6 determined whether the provider was utilizing cognitive testing for 
patients at risk for cognitive impairment and specified which cognitive tests were being 
conducted, such as the Mini-Mental State Exam (MMSE), the Mini-Cog test, the General 
Practitioner Assessment of Cognition test (GPCOG), or other cognitive tests. Question 7 
determined if the provider was aware of the research regarding genetic screening for 
Alzheimer’s disease. Question 8 was related to the research questions and determined if 
genetic screening was being offered or utilized in individuals at an increased risk for 
developing Alzheimer’s disease.  Question 9 was a “select all that apply” question and 
provided the reason genetic screening was not utilized, including time constraints, 
insurance coverage, or patient refusal.  Lastly, question 10 was a “select all that apply” 
question and assisted in determining provider follow up plan of care which included 
neurology referral, social services consult, medication for dementia, and/or genetic 
counseling.  Those who chose to participate in this study had their answers submitted  
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anonymously, and the data was compiled, evaluated, and analyzed to determine the 
significance of the research study.  
Protection of Human Subjects 
 The study was performed once permission was granted from the Institutional Review 
Board of Mississippi University for Women.  Human Subjects were utilized in the 
conduction of this study through the completion of a survey questionnaire.  The survey 
 
 
determined if genetic screening was being offered to at-risk individuals by primary care 
providers throughout the state of Mississippi.  Strict caution was taken to maintain 
participant privacy and anonymity as data was being collected. No identifying indicators 
were revealed, including the participant name or affiliated clinic name.  The researchers 
utilized a reliable, non-traceable survey building website, Survey Monkey, Inc.  The data 
collected was stored in a secure location until analyzed and destroyed once the analysis 
was concluded.  Once the account on Survey Monkey, Inc. was deactivated, all obtained 
data information was also destroyed. This policy can be located on the Survey Monkey, 
Inc. website.  The data obtained was only used for this research project and was not 
shared with any affiliated or non-affiliated persons or organizations.  
Summary 
 In conclusion, the researchers hoped to provide education on the importance of genetic 
screening in individuals identified with an increased risk of developing Alzheimer’s 
disease.  This research was conducted through surveys distributed across the state of 
Mississippi to primary health care providers.  This allowed the researchers to gather data 
and determine if individuals were being evaluated and assessed to determine the presence  
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of risk factors that placed them at a higher risk of developing Alzheimer’s disease.  It also 
allowed the researchers to determine if genetic screening was being offered to those at-
risk individuals and identified the most common reasons why genetic screening was not 
offered.  Identifying these individuals and promoting genetic screening will allow for 






















CHAPTER IV  
Presentation of Findings 
 Alzheimer’s disease is a progressive neurological illness that affects thousands of 
individuals every year.  The problem was determining whether genetic screening was 
being fully utilized in the primary care setting for patients that exhibit increased risk 
factors which include increased age, family history, diabetes, hypertension, obesity, 
smoking, depression, cognitive inactivity, physical inactivity, low education, specific 
 
 
genetic markers (APOE-e4) that predispose individuals to Alzheimer’s disease. 
Identifying individuals with increased risk factors is essential because early intervention 
could provide a solution to controlling this disease and providing statistics for future 
research.  The purpose of this study was to determine if genetic screening was being 
utilized in the primary care setting for individuals who are at increased risk for 
developing Alzheimer’s disease.  The study sought to determine if signs of Alzheimer’s 
disease were recognized quickly in the primary care setting.  Surveys were distributed to 
various primary health care providers across the state of Mississippi to determine whether 
genetic screening was being offered to individuals considered at-risk for developing 
Alzheimer's disease.  The researchers created a survey using a reliable survey building 
website, Survey Monkey, Inc. (see Appendix B).  These surveys served as data collection 
tools and assisted in determining if providers were able to recognize those at risk for 
developing Alzheimer's disease based on the Alzheimer's Association guidelines, and if 
those patients were being offered genetic screening.  The data was collected from the 
surveys and entered in an Excel document.  Information obtained from this study will be 
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used to help primary providers identify and promote awareness of the signs and risk 
factors of Alzheimer’s disease in their patients.   
Participant Characteristics 
Data for the study were obtained from Survey Monkey, Inc. a reliable survey 





that targeted primary care providers, physician assistants, nurse practitioners, and 
physicians. The survey was made available to hundreds of health care providers across 
the state of Mississippi. The sample respondents included 20 participants.  Of the 20 
participants, 18 participants indicated they were nurse practitioners.  The other 2 
respondents indicated that they were either a family nurse practitioner or a nurse 
practitioner student.   
Findings 
 The study concluded with a summation of findings that identified if patients with 
increased risk for Alzheimer’s disease were being identified in the primary care setting 
and if primary care providers are utilizing genetic screening for high risk patients for 
Alzheimer’s disease.  The research tool provided included ten questions.  The questions 
consisted of type of care provider, area of practice, awareness of risk factors, how often 
did the provider assess for risk factors, utilization of cognitive testing, tests used, reasons 
for not utilizing genetic screening, and what follow up plan of care was used for patients 
exhibited signs of Alzheimer’s disease.   
When reviewing the data of the study population, the title of care provider was 
assessed first (See Figure 1).  Of the 20 participants, 90% of the care providers indicated  
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that they were nurse practitioners (n=18) and 10% indicated they were either a family 
nurse practitioner or a nurse practitioner student (n=2).  The next question asked the 
participant what his or her area of practice was;  65% (n=13) responded that they were in 
primary practice, 20% in primary care (n=4), and 15% (n=3) indicated that they practiced 
in another setting, which included the emergency room, nursing homes, and inpatient 
 
 
behavioral health & addiction (See Figure 2).  Of the 20 participants, 80% (n=16) 
responded that they were aware of the risk factors that predispose patients to developing 
Alzheimer’s disease, whereas 20% (n=4) said that they were not aware of these risk 
factors (See Figure 3).  The next question asked the care provider if they routinely 
assessed or risk factors for Alzheimer’s disease.  The survey showed that 70% of the 
respondents (n=14) indicated that they routinely assessed risk factors for Alzheimer’s 
disease (age, family history, diabetes, hypertension, obesity, smoking, depression, 
cognitive inactivity, physical inactivity, and low education) and 30% (n=6) said they do 
not (See Figure 4).  When asked if the care provider utilized cognitive testing for 
individuals with increased risk for cognitive impairment or Alzheimer’s disease, most 
respondents (70%  (n=14)) indicated they utilize cognitive testing for individuals with 
increased risk for cognitive impairment or Alzheimer’s disease and 30% (n=6) said that 
they do not utilize cognitive testing (See Figure 5).  The next question asked participants 
what tests they utilized for testing individuals with increased risk of Alzheimer’s disease .  
Most respondents (65%; N=13) indicated using the MMSE for cognitive testing, either 
alone or in combination with GDS.  The percentage of providers who used the Mini-
Mental State Exam (MMSE) test was 50% (n=10), the Mini-Mental State Exam +  
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Geriatric Depression Scale  (MMSE + GDS) test was 15% (n=3), the Cambridge 
Cognition Exam (CAMCOG) test was 5% (n=1), and No Test Used was 30% (n=6) (See 
Figure 6).  Only 50% of the respondents (n=10) were aware of research regarding genetic 
screening and Alzheimer’s disease, and none of the respondents used genetic screening 





reasons for not utilizing genetic screening for individuals with increased risk for 
Alzheimer’s disease.  Those citing insurance coverage concerns were 45% (n=9), 
insurance coverage + time restraints 20% (n=4), patient refusal 5% (n=1), time restraint 
concerns 10% (n=2), and other reasons 20% (n=4) (See Figure 7).  The most common 
reason for not utilizing genetic screening for individuals with increased risk for 
Alzheimer’s disease was Insurance Coverage, 65% (n=13).  Of the respondents citing 
insurance coverage as the reason for not utilizing genetic screening, 4 respondents also 
cited time restraints.  Time restraints was the second leading reason cited for not using 
genetic screening 30% (n=6). Respondents citing other reasons included: 1 being 
unaware of genetic testing and 3 indicating their area of practice was the reason 
(Emergency Room, Orthopedics, and 1 did not specify).  The respondents next indicated 
that if the patient screening determined risk factors that predispose the patient to 
Alzheimer’s disease, the follow up plan of care would include the following and all that 
would apply.  Follow up plan of care reported was neurology at 65% (n=13), education 
related to Alzheimer’s disease and plan of care at 45% (n=9), medication therapy at 40% 
(n=8), lifestyle modification at 30% (n=6), social services consult at 20% (n=4), genetic 
screening/counseling at 10% (n=2), and Alzheimer’s support group at 10% (n=2).  Most  
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(70%) respondents selected more than one item from the follow up plans of care list. 
Below is a bar graph that summarizes the actual plans of care indicated by respondents 
(See Figure 8).  The final question asked providers if the patient screening determines 
risk factors that predispose the patient to developing Alzheimer’s disease, as well as what 
his or her follow up plan of care would include.  The responses were the following:  none 
 
 
indicated at 10% (n=2), neurology referral at 20% (n=4), social services consult at 5% 
(n=1), education related to Alzheimer's disease and plan of care (education) at 5% (n=1), 
neurology referral + medication therapy at 5% (n=1), neurology referral + medication 
therapy + education at 10% (n=2), neurology referral + medication therapy + lifestyle 
modification at 5% (n=1), social services + medication therapy + lifestyle modification at 
5% (n=1), medication therapy + support group + education at 5% (n=1), genetic 
screening + education + lifestyle modification at 5% (n=1), neurology referral + 
education + genetic screening at 5% (n=1), neurology referral + education + support 
group at 5% (n=1), neurology referral + education + social services consult at 5% (n=1), 
neurology referral + lifestyle modification at 5% (n=1), neurology referral + education + 












Figure 1, Primary Care Providers 
 
 





















Figure 5, Utilize Cognitive Testing 
 
 




















Figure 9, Risk Factors Follow Up 
 
Statistical Findings 
      The purpose of this study was to determine if genetic screening was being utilized in the 
primary care setting for individuals who are at increased risk for developing Alzheimer’s 
disease. The research study produced 20 respondents in this sample. Eighteen of the 20 
participants (90%) identified as being Nurse Practitioners. The other two respondents indicated 
that they were Family Nurse Practitioners or Nurse Practitioner students. When respondents 
indicated their area of practice, 65% (N=13) responded that they were in primary practice, 20% 
in primary care (N=4), and 15% (N=3) indicated that they practiced in another setting, which 















Research Question 2 
Are primary care providers utilizing genetic screening for patients who are at 
increased risk of developing Alzheimer's disease?  The answer to this question, based on 
this sample of respondents is no. None of the 13 primary care providers utilized genetic 
screening for individuals with increased risk for Alzheimer’s disease.  
 
 











Insurance Coverage 6 46.2 46.2 46.2 
Time Restraints 1 7.7 7.7 53.8 
Patient Refusal 1 7.7 7.7 61.5 
Insurance Coverage + Time 
Restraints 
4 30.8 30.8 92.4 
Other- Unaware of test 1 7.7 7.7 100.0 
Total 13 100.0 100.0  












Figure 11, Reasons for Not Utilizing Genetic Screening 
 
Summary 
In total, 20 surveys were collected from participants across the state of 
Mississippi.  The research study addressed the research questions set for this study.  It 
was sought to determine if genetic screening was being utilized in the primary care 
setting for individuals who are at increased risk for developing Alzheimer's disease. The 
study revealed that primary care providers are aware of patients that exhibit signs for high 
risk of developing Alzheimer’s disease.  The second research question was also 
addressed when respondents were asked if they were utilizing genetic screening for those 






acknowledged they were aware of the research regarding genetic screening and the 
disease.  There was no data collected that confirmed genetic screening was being offered 
























Summary and Conclusions 
Alzheimer's disease is an irreversible, progressive disease of the brain that slowly 
begins with the destruction of memory and cognition and eventually leads to the inability 
to perform necessary activities of daily living. This disorder of the brain is a substantial 
health problem and the disease occurrence is increasing with the aging population. 
Unfortunately, there is no standard screening protocol for the diagnosis and progression 
of the disease.  It is the sixth leading cause of death in the United States, accounting for 
almost 4% of all deaths in 2014 (CDC, 2017). Current disease management focuses on 
preserving memory and cognition and managing behavioral symptoms. The researchers 
sought to determine if providers in the primary care setting were identifying 
individuals/patients at increased risk of developing Alzheimer's. Factors that increased 
the risk of Alzheimer’s disease was defined to include advanced age, family history, 
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, physical 
inactivity, and low education. The researchers also sought to determine if primary care 
providers were offering and utilizing genetic screening for those individuals/patients who 
were identified with positive risk factors for developing Alzheimer’s. The researchers 
used Nola Pender’s Health Promotion Model (HPM) as the theoretical framework to 
guide this study. 
After reviewing the literature associated with this ongoing health problem, it was 







predispositions to the disease, such as hypertension or diabetes, could invoke lifestyle 
changes that could modify the progression of the disease. The researchers determined that 
early intervention could be a substantial component in controlling this disease by 
identifying patients in primary care who are at high risk for developing Alzheimer's 
before the clinical onset of the disease, and those with positive risk factors. These genetic 
variations can later be further identified and aid providers with definitive diagnosis and 
interpretation of risk for those individuals and their families. 
The e4 allele of apolipoprotein E (APOE) gene poses the most substantial risk 
concerning the development of the disease. It is included in many of the clinical trials and 
research studies discussed in the review of literature, such as Tasaki et al., where the 
study determined that the APOE genotype was the superior predictor of Alzheimer's 
disease. Along with this, Yokoyama et al. also reiterated the strong genetic correlation to 
Alzheimer’s disease and further supported the APOE genotype as being the most 
significant risk factor of the potential diagnosis. In this research study patients underwent 
cognitive testing prior to genetic testing and had to score at least a 26 on the Mini-Mental 
State Exam score or a 0 on the Clinical Dementia Rating Scale. Genetic testing was then 
done to test for the APOE gene, and the patients were followed closely with weekly 
cognitive testing to investigate mental decline. This research provided improved risk 
assessments on individuals based on the presence of the APOE genotype aided them in 
diagnosis and potentially clarifying risks for the patient and family members affected by 
the disease. The current research project sought to exemplify the strong genetic 




testing. While this importance was conveyed, there were no primary care providers 
within the current research study that stated the utilization of genetic testing. Evanson et 
al. actually found in the research study that physicians expressed immense knowledge of 
genetic testing but lower levels of confidence about communicating that knowledge with 
their patients. The current research study did determine lack of knowledge of genetic 
testing related to Alzheimer’s disease as a reason genetic testing was not performed or 
offered. Along with this, the study by Brodaty et al. revealed time investment as a 
significant limitation in providing cognitive screening to the elderly. This was also true in 
the current research study performed. A large portion of responses expressed time 
constraints as a reason for not utilizing or performing genetic testing on individuals at 
risk for developing Alzheimer’s disease. 
  In this study, the researchers used a quantitative survey as the design for data 
collection. Strict caution was taken once approval was granted by the Institutional 
Review Board at Mississippi University for Women to ensure participant privacy and 
anonymity as data was collected. The researchers provided questions in the survey using 
SurveyMonkey, Inc. This survey included demographic data, the determination of 
provider assessments, the evidence of genetic screening offered, the cognitive 
assessments used, the reason genetic screening was not utilized, and the follow-up care 
provided for those who chose genetic screening. The sample size was 20. Upon 
completion of the data collection, the researchers determined that genetic testing was not 







discussion of the findings along with implications, limitations, and recommendations will 
be discussed for the remainder of the chapter. 
Interpretation of Findings and Conclusions 
The purpose of this study was to determine if genetic screening was being utilized 
in the primary care setting for individuals at increased risk of developing Alzheimer's 
disease. The researchers had 20 respondents in this sample. Eighteen of the 20 
participants (90%) identified as being Nurse Practitioners. The other two respondents 
indicated that they were Family Nurse Practitioners or Nurse Practitioner students. When 
respondents indicated their area of practice, 65% (N=13) responded that they were in 
primary practice, 20% in primary care (N=4), and 15% (N=3) indicated that they 
practiced in another setting, which included the ER, nursing homes, and inpatient 
behavioral health & addiction. When the respondents were asked if they were aware of 
genetic screening for Alzheimer’s disease, only 50% of the respondents (N=10) 
acknowledged they were aware of the research regarding genetic screening and 
Alzheimer’s disease. When questioned if the risk factors of Alzheimer’s disease were 
routinely assessed, including age, family history, diabetes, hypertension, obesity, 
smoking, depression, cognitive inactivity, physical inactivity, and low education, 70% of 
the respondents (N=14) indicated that they did routinely assess for these risk factors. The 
participants were questioned if they utilized cognitive testing for individuals with 
increased risk for cognitive impairment or Alzheimer’s disease, and most of the 
respondents (70%, N=14) indicated that they did utilize cognitive testing routinely. Of the 




(MMSE) was selected as the primary assessment for cognitive testing. The respondents 
replied that they utilized the MMSE either alone or in combination with the Geriatric 
Depression Scale. When the research question was asked to determine whether genetic 
screening was offered or utilized in patients with an increased risk of developing 
Alzheimer's, none of the respondents stated utilization of genetic screening for 
individuals with increased risk for Alzheimer’s disease. When questioned about the 
reasoning of not utilizing genetic testing, the respondents 65% (N=13) indicated 
insurance coverage prevented them from offering genetic testing. Of the respondents 
stating insurance coverage as a reason not to utilize genetic screening, four respondents 
also stated time restraints as a limitation.  Time restraints were the second leading reason 
cited for not using genetic screening (30%; N=6). Four respondents cited other reasons 
genetic testing was not utilized, including one respondent unaware of genetic testing, and 
three respondents in an area of practice where it was not considered applicable (ER, 
Orthopedics, and one did not specify). According to the results of this survey, patients 
who are at increased risk of developing Alzheimer's disease are being identified and 
screened. Thirteen of the respondents work in a primary care setting.  Of these, 76.9% 
(N=10) routinely assessed risk factors for Alzheimer's disease. Of those who routinely 
assessed risk factors of Alzheimer's disease, eighty percent (N=10) utilized cognitive 
testing for these individuals at increased risk for developing Alzheimer's Disease. Genetic 
testing was not being offered or utilized within the primary care setting to individuals at 
risk for developing Alzheimer’s. While most primary care providers were identifying and 






primary care providers who participated in the survey offered or utilized genetic 
screening for these identified individuals. Of the 13 primary care providers identified, the 
key reasons chosen for not utilizing genetic screening was lack of insurance coverage 
(76.9%; N=10) and patient/provider time restraints (38.5%; N=5). To determine the 
follow up plan of care once risk factors had been identified,, the respondents were 
provided with a question in the format of selecting all that apply. The following options 
were listed: neurology referral, social services consult, education related to Alzheimer’s 
and plan of care, lifestyle modifications, genetic counseling, and medication therapy. 
Seventy percent of respondents selected a combination of the listed options. Two of the 
respondents selected that they would not include any of the options in the at-risk patient’s 
follow-up plan of care. Four respondents (20%) selected a neurology referral alone, while 
one respondent (5%) selected only a social services consult. One respondent (5%) opted 
to utilize only education regarding Alzheimer's disease. Two respondents (10%) selected 
a combination of medication therapy, education regarding Alzheimer’s disease, and 
neurology referral as their preferred follow-up plan of care. One respondent (5%) 
selected a neurology referral and medication as a desired plan of care while another 
respondent (5%) selected neurology referral, medication therapy, in addition to lifestyle 
modifications. One respondent (5%) chose to utilize social services, medication, and 
lifestyle modifications, while another respondent (5%) relied on medication, genetic 
counseling, and education regarding the disease process. Another respondent (5%) 
selected genetic screening, medication, and lifestyle modifications, while a separate 




counseling over lifestyle modifications. Another (5%) respondent opted for a neurology 
referral, education regarding respondent Alzheimer's, and lifestyle modifications while 
another respondent (5%) only selected a neurology referral and education. The final 
respondent (5%) selected a neurology referral and a social service consult regarding the 
treatment plan of care of an individual identified as at increased risk of developing 
Alzheimer's. Overall, 13 of the 20 respondents selected either alone or in combination to 
refer to their patient identified to be at an increased risk of developing Alzheimer's to 
neurology for management of the disease process. While none of the survey participants 
offered or utilized genetic screening to individuals at risk for developing Alzheimer’s, 
two of the respondents did include genetic screening along with a combination of other 
options in their proposed plan of care. 
There were two research questions addressed in this study. Are patients at 
increased risk for developing Alzheimer's disease being identified by providers in the 
primary care setting; and are primary care providers utilizing genetic screening for 
patients at increased risk for developing Alzheimer's disease?  When reviewing the 
current practices for screening patients of patients with increased risk, seventy-nine 
percent of providers routinely assessed risk factors for Alzheimer's disease.  Eighty 
percent of the respondents identified as utilizing cognitive testing.   None of the 
respondents offered genetic testing for the patients at increased risk for developing 








The findings of the current researchers were similar to those of Brodaty et al. in that both 
studies suggest that cognitive testing is beneficial for a timely diagnosis of Alzheimer's 
disease. 
Limitations 
The limitations of the study which were identified prior to data collection were 
only a small geographical area was studied, a small sample size being collected, and 
limited distribution of the study was distributed via social media outlets to distribute to 
the appropriate audience, this limitation only included feedback from Nurse Practitioners 
which limited access to gather and collect data. The research questions only addressed 
primary care providers, neglecting those that work in specialty areas such as neurology, 
and psychology that are also capable of utilizing genetic testing, thereby limiting the 
range of responses. The reliability of survey data was also considered a limitation not due 
to the respondents providing accurate honest answers. Lack of confidence in the subject 
area could also limit the study to biased responses.  
The major limitation on the research study was a global pandemic.  COVID-19 
created numerous limitations in health care and prevented researchers from hands on 
collection of data.  Alzheimer's disease is the most common cause of dementia. This 
disease occurs worldwide and affects all ethnic groups. The findings concluded in this 
study were that patients who are at increased risk of developing Alzheimer's disease are 
being identified and screened, and over half of the respondents identified as routinely 
assessing risk factors. Those who regularly evaluate risk factors (80%) utilize cognitive 




aware of research regarding genetic screening.  The researchers concluded that none of 
the respondents used or offered genetic screening for individuals with increased risk for 
Alzheimer's disease. The primary reason for not using or offering genetic screening for 
individuals with increased risk for Alzheimer’s disease as insurance coverage.  
Implications and Recommendations 
It is estimated by 2050, 16 million people will be diagnosed with Alzheimer's 
(CDC, 2017). It is the sixth leading cause of death in the United States (CDC,2017). 
Modifiable risk factors such as diet, and cognitive challenges have been shown to slow 
the disease process (CDC, 2017). Medical management can improve the quality of life 
for individuals living with Alzheimer’s disease and their caregivers.  There is currently 
no known cure for Alzheimer’s disease. In order to provide education on modifiable risk 
factors, the providers must be aware and up to date on genetic screenings. 
Our research project revealed that although Primary Care Providers in Mississippi 
are aware of the availability of genetic screening, very few are utilizing genetic testing 
for patients with increased risk for Alzheimer's disease. The most common reason for not 
implementing genetic screening for their patients with risk factors for Alzheimer's was 
insurance coverage, followed by time restraints. This study implies that even though the 
awareness is there, the resources are not utilized. With the results of this research study, 
providers can explore opportunities to implement better screening and utilization of 
existing resources into their practices. This survey was specifically designed to test the 
knowledge and utilization of the available testing for patients at an increased risk of 






implement lifestyle changes that could prolong the patient's quality of life.  The nursing 
theory used in this study shows that a patient will do better if they know to do so. 
Increasing knowledge not only increases awareness for the patient but the provider, as 
well. 
Recommendations that arise from the results of this research study include 
increasing awareness of the benefits of genetic testing for patients with increased risk of 
developing Alzheimer's Disease as well as increasing the sample size and the 
geographical area.  Mass marketing on Social media and television could encourage 
patients to start asking questions about their care, and the options they have. When 
patients are included in their plan of care, they are better to adhere to treatment options, 
and make those lifestyle changes to prevent or slow the progression of developing the 
disease. Future research could expand their sample size by doing paper surveys, as well 
as face to face interviews to obtain feedback. Educating Primary Care Providers and the 
public would increase the demand for such testing. Education plays a significant factor in 
the lack of use of any resource. Education on the benefits of early intervention for those 
at-risk patients, for their families, as well as the Primary Care Provider, would also 
increase the usage of this resource. Recommendations for Advanced Nursing Practice is 
the implementation of a guideline for screening would be beneficial. For example, in the 
electronic medical record (EMR), there could be screening questions that target cognitive 
decline. There could be standardized steps to implement in the early stages of decline. 
More focus on family history should be a talking point with the patient. Family history 




Insurance Coverage was the most common factor that prevented the utilization of genetic 
screening. If providers utilize genetic testing more frequently, insurance companies will 
begin to include it in their covered benefits. Also, lobby for insurance coverage for 
genetic screening as a preventative service to decrease the patient's rate of decline, which, 
in turn, reduces insurance pay-out. 
Recommendation for future research can be done to assess the provider willingness to 
utilize genetic testing if education was more readily available, and insurance coverage 
was not an issue. If all of the stated barriers were removed, what would be the patient's 
increased benefit? Would their quality of life be improved? Would the patient change 
anything about their lifestyle? Would mental health be more of a priority in the routine 
care of patients? These questions could be the starting points for future discussions. 
Summary 
This study was conducted to provide education on the importance of genetic 
screening in individuals identified with an increased risk of developing Alzheimer’s 
disease.  The study was conducted through a quantitative survey distributed to health care 
providers across the state of Mississippi.  This allowed researchers to gather data and 
determine if individuals who were at increased risk of developing Alzheimer’s disease 
were being identified and offered genetic screening.  While the study revealed most 
primary care providers were identifying and screening these individuals who were at 
increased risk for developing Alzheimer's, none of the providers that participated in the 
survey offered or utilized genetic screening for these identified individuals. The study 






which was found to be time constraints and insurance coverage.  Studies have been 
conducted to prove the identification of individuals with increased risks of Alzheimer’s 
disease and the promotion of genetic screening in the primary care setting would allow 
for yearly follow up, genetic counseling, early detection of cognitive decline, and early 
intervention. There are many limitations to this study that can be improved upon and 
corrected for future research.  This study provides a substantial foundation and realization 
that although risk factors are being identified in the primary care setting, genetic 
screening is not being offered.  Utilization of this data, along with further research will be 
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Instructions to participants are as follows: 
● By completing this survey, you are giving consent to participate. 
● This survey is both a demographic and data collection survey to determine if 
genetic testing is utilized in the primary care setting for individuals with an 
increased risk of Alzheimer's disease. 
● Participants will remain anonymous. 
● No participant shall identify their employment facility. 
 
Please select the most appropriate answer to the following questions: 
1. Please select which best applies. 
A. Doctor of Medicine (M.D.) 
B. Doctor of Osteopathic Medicine (D.O.) 
C. Nurse Practitioner 
D. Physician’s Assistant  
E. Other:_________________________ 
 
2. Please select which best describes your area of practice. 
A. Primary Care Clinic 
B. Urgent Care Clinic 
C. Specialty Care Clinic / Other:____________________ 
 












4. Do you routinely assess risk factors for Alzheimer’s Disease (age, family history, 
diabetes, hypertension, obesity, smoking, depression, cognitive inactivity, 




5. Do you utilize cognitive testing for individuals with increased risk for cognitive 








D. Geriatric Depression Scale (GDS) 
E. Other 
 













9. If no, what are your reasons for not utilizing genetic screening for individuals 
with increased risk for Alzheimer's disease?  Select all that apply. 
A. Insurance coverage/ Cost to patient 
B. Time restraints 
C. Patient refusal 
 
10. If the patient screening determines risk factors that predispose to Alzheimer's 
disease, does your follow up plan of care include: Select all that apply. 
1. Neurology referral 
2. Social services consult 
3. Medication for dementia 
4. Genetic screening/counseling 
5. Alzheimer’s support group 























There were 20 respondents in this sample. Eighteen of the 20 participants (90%) 
indicated being Nurse Practitioners. The other two respondents indicated that they were 
FNP or NP students.   
 
Professional title 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Nurse Practitioner 18 90.0 90.0 90.0 
FNP/NP Student 2 10.0 10.0 100.0 
Total 20 100.0 100.0  
 
When indicated the area of practice, 65% (N=13)responded that they were in Primary 
practice, 20% in primary care (N=4), and 15% (N=3) indicated that they practiced in 
another setting, which included the ER, Nursing homes, and Inpatient Behavioral Health 
& Addiction.   
 
Are you aware of the risk factors that predispose patients to developing 
Alzheimer's disease? 
 Frequency Percent Valid Percent Cumulative Percent 
Valid No 4 20.0 20.0 20.0 
Yes 16 80.0 80.0 100.0 
Total 20 100.0 100.0  
 
70% of the respondents (N=14) indicated that they routinely assessed risk factors for 
Alzheimer’s disease (age, family history, diabetes, hypertension, obesity, smoking, 
depression, cognitive inactivity, physical inactivity, and low education) 
 
Do you routinely assess risk factors for Alzheimer’s disease (age, family 
history, diabetes, hypertension, obesity, smoking, depression, cognitive 
inactivity, physical inactivity, and low education) in your clinical practice? 
 Frequency Percent Valid Percent Cumulative Percent 
Valid No 6 30.0 30.0 30.0 
Yes 14 70.0 70.0 100.0 














Again, most of the respondents (70%, N=14)) indicated that they utilize cognitive testing 
for individuals with increased risk for cognitive impairment or Alzheimer’s disease. 
Do you utilize cognitive testing for individuals with increased risk for 
cognitive impairment or Alzheimer’s disease? 
 Frequency Percent Valid Percent Cumulative Percent 
Valid No 6 30.0 30.0 30.0 
Yes 14 70.0 70.0 100.0 
Total 20 100.0 100.0  
 
Most respondents (65%; N=13) indicated using the MMSE for cognitive testing, either 
alone or in combination with GDS. 
Test utilized 
 Frequency Percent Valid Percent Cumulative Percent 
Valid No test used 6 30.0 30.0 30.0 
MMSE 10 50.0 50.0 80.0 
MMSE + GDS 3 15.0 15.0 95.0 
CAMCOG 1 5.0 5.0 100.0 
Total 20 100.0 100.0  
 
Only 50% of the respondents (N=10) were aware of research regarding genetic screening 
and Alzheimer’s disease, and none of the respondents used genetic screening for 
individuals with increased risk for Alzheimer’s disease. 
The most common reason for not utilizing genetic screening for individuals with 
increased risk for Alzheimer’s disease was Insurance Coverage, 65% (N=13) of 
respondents indicating that this was a reason. Of the respondents citing insurance 
coverage as a reason not to utilize genetic screening, four respondents also cited time 
restraints.  Time restraints was the second leading reason cited for not using genetic 
screening (30%; N=6). Four respondents cited other reasons, including one being 
unaware of genetic testing and three indicated their area of practice (ER, Orthopedics, 
one did not specify). 
 
Reasons for not utilizing genetic screening for individuals with increased 
risk for Alzheimer's disease 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Insurance Coverage 9 45.0 45.0 45.0 
Time Restraints 2 10.0 10.0 55.0 
Patient Refusal 1 5.0 5.0 60.0 
Insurance Coverage + Time 
Restraints 
4 20.0 20.0 80.0 
Other 4 20.0 20.0 100.0 
     
Total 20 100.0 100.0  
The respondents indicated that if the patient screening determine risk factors that 










Follow up plan of care reported Frequency Percentage 
Neurology 13 65.0 
Education related to Alzheimer’s disease and plan of care 9 45.0 
Medication Therapy 8 40.0 
Lifestyle modification 6 30.0 
Social Services Consult 4 20.0 
Genetic Screening/Counseling 2 10.0 
Alzheimer’s Support Group 2 10.0 
 
Most (70%) of respondents selected more than one item from the follow up plans of care 
list. Below is a table that summarizes the actual plans of care indicated by respondents.   
 
If the patient screening determines risk factors that predispose to 
Alzheimer's disease, does your follow up plan of care include: 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid None indicated 2 10.0 10.0 10.0 
Neurology referral 4 20.0 20.0 30.0 
Social Services Consult 1 5.0 5.0 35.0 
Education related to 
Alzheimer's disease and 
plan of care (Education) 
1 5.0 5.0 40.0 
Neurology referral + 
Medication Therapy 




2 10.0 10.0 55.0 
Neurology referral + 
Medication Therapy + 
Lifestyle Modification 
1 5.0 5.0 60.0 
Social Services + Medication 
Therapy+ Lifestyle 
modification 
1 5.0 5.0 65.0 
Medication Therapy 
+Support Group +Education 








1 5.0 5.0 80.0 
Neurology Referral + 
Education + Support Group 
1 5.0 5.0 85.0 
Neurology referral +Social 
Services Consult 
1 5.0 5.0 90.0 
 
 
Neurology Referral + 
Lifestyle modification 




1 5.0 5.0 100.0 
Total 20 100.0 100.0  
 
Research Questions: 
1.      Are patients who are at increased risk of developing Alzheimer's disease being 
identified by providers in the primary care setting? 
According to the results of this survey, patients who are increased risk of developing 
Alzheimer’s disease are being identified and screened.  Thirteen of the respondents work 
in a primary care setting.  Of these, 76.9% (N=10) routinely assess risk factors for 
Alzheimer’s disease. Of those that routinely assess risk factors of Alzheimer’s disease, 
80% (N=10), utilize cognitive testing for these individuals at increased risk.   
 
2.       Are primary care providers utilizing genetic screening for patients who are at increased 
risk of developing Alzheimer's disease? 
The answer to this question, based on this sample of respondents is no. None of the 13 primary 
care providers offers/utilized genetic screening for individuals with increased risk for 
Alzheimer’s disease. For this subset of the sample, the primary reasons given for not using 
genetic screening in Insurance Coverage (76.9%; N=10) and Patient/Provider time restraints 
(38.5%; N=5).   
 
 
Reasons for not utilizing genetic screening for individuals with increased 
risk for Alzheimer's disease 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Insurance Coverage 6 46.2 46.2 46.2 
Time Restraints 1 7.7 7.7 53.8 
Patient Refusal 1 7.7 7.7 61.5 
Insurance Coverage + Time 
Restraints 
4 30.8 30.8 92.4 
Other- Unaware of test 1 7.7 7.7 100.0 
Total 13 100.0 100.0  
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